Cargando…
Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain
The discovery and development of antimicrobial therapies represents one of the most significant advancements in modern medicine. Although the primary therapeutic intent of antimicrobials is to eliminate their target pathogens, several antimicrobials have been shown to provide analgesia as a secondar...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Pain Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322666/ https://www.ncbi.nlm.nih.gov/pubmed/37394273 http://dx.doi.org/10.1101/2022.11.03.22281783v1.abstract |
_version_ | 1785068808047689728 |
---|---|
author | Wang, Eric J. Dolomisiewicz, Edward Karri, Jay Tontisirin, Nuj Cohen, Steven P. |
author_facet | Wang, Eric J. Dolomisiewicz, Edward Karri, Jay Tontisirin, Nuj Cohen, Steven P. |
author_sort | Wang, Eric J. |
collection | PubMed |
description | The discovery and development of antimicrobial therapies represents one of the most significant advancements in modern medicine. Although the primary therapeutic intent of antimicrobials is to eliminate their target pathogens, several antimicrobials have been shown to provide analgesia as a secondary benefit. Antimicrobials have demonstrated analgesic effects in conditions that involve dysbiosis or potential subclinical infection (e.g., chronic low back pain with Modic type 1 changes; chronic prostatitis/chronic pelvic pain; irritable bowel syndrome; inflammatory bowel disease; functional gastrointestinal disorders/dyspepsia; myalgic encephalomyelitis/chronic fatigue syndrome), and might even prevent the chronification of pain after acute infections that are associated with excessive systemic inflammation (e.g., post COVID-19 condition/long Covid, rheumatic fever). Clinical studies often assess the analgesic effects of antimicrobial therapies in an observational manner, without the ability to identify causative relationships, and significant gaps in the understanding remain regarding the analgesic potential of antimicrobials. Numerous interrelated patient-specific, antimicrobial-specific, and disease-specific factors altogether contribute to the perception and experience of pain, and each of these requires further study. Given worldwide concerns regarding antimicrobial resistance, antimicrobials must continue to be used judiciously and are unlikely to be repurposed as primary analgesic medications. However, when equipoise exists among several antimicrobial treatment options, the potential analgesic benefits of certain antimicrobial agents might be a valuable aspect to consider in clinical decision-making. This article (the second in a two-part series) aims to comprehensively review the evidence on the prevention and treatment of chronic pain using antimicrobial therapies and suggest a framework for future studies on this topic. |
format | Online Article Text |
id | pubmed-10322666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Korean Pain Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-103226662023-07-07 Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain Wang, Eric J. Dolomisiewicz, Edward Karri, Jay Tontisirin, Nuj Cohen, Steven P. Korean J Pain Review Article The discovery and development of antimicrobial therapies represents one of the most significant advancements in modern medicine. Although the primary therapeutic intent of antimicrobials is to eliminate their target pathogens, several antimicrobials have been shown to provide analgesia as a secondary benefit. Antimicrobials have demonstrated analgesic effects in conditions that involve dysbiosis or potential subclinical infection (e.g., chronic low back pain with Modic type 1 changes; chronic prostatitis/chronic pelvic pain; irritable bowel syndrome; inflammatory bowel disease; functional gastrointestinal disorders/dyspepsia; myalgic encephalomyelitis/chronic fatigue syndrome), and might even prevent the chronification of pain after acute infections that are associated with excessive systemic inflammation (e.g., post COVID-19 condition/long Covid, rheumatic fever). Clinical studies often assess the analgesic effects of antimicrobial therapies in an observational manner, without the ability to identify causative relationships, and significant gaps in the understanding remain regarding the analgesic potential of antimicrobials. Numerous interrelated patient-specific, antimicrobial-specific, and disease-specific factors altogether contribute to the perception and experience of pain, and each of these requires further study. Given worldwide concerns regarding antimicrobial resistance, antimicrobials must continue to be used judiciously and are unlikely to be repurposed as primary analgesic medications. However, when equipoise exists among several antimicrobial treatment options, the potential analgesic benefits of certain antimicrobial agents might be a valuable aspect to consider in clinical decision-making. This article (the second in a two-part series) aims to comprehensively review the evidence on the prevention and treatment of chronic pain using antimicrobial therapies and suggest a framework for future studies on this topic. The Korean Pain Society 2023-07-01 2023-07-01 /pmc/articles/PMC10322666/ /pubmed/37394273 http://dx.doi.org/10.1101/2022.11.03.22281783v1.abstract Text en © The Korean Pain Society, 2023 https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Wang, Eric J. Dolomisiewicz, Edward Karri, Jay Tontisirin, Nuj Cohen, Steven P. Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain |
title | Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain |
title_full | Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain |
title_fullStr | Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain |
title_full_unstemmed | Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain |
title_short | Antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain |
title_sort | antimicrobial therapies for chronic pain (part 2): the prevention and treatment of chronic pain |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322666/ https://www.ncbi.nlm.nih.gov/pubmed/37394273 http://dx.doi.org/10.1101/2022.11.03.22281783v1.abstract |
work_keys_str_mv | AT wangericj antimicrobialtherapiesforchronicpainpart2thepreventionandtreatmentofchronicpain AT dolomisiewiczedward antimicrobialtherapiesforchronicpainpart2thepreventionandtreatmentofchronicpain AT karrijay antimicrobialtherapiesforchronicpainpart2thepreventionandtreatmentofchronicpain AT tontisirinnuj antimicrobialtherapiesforchronicpainpart2thepreventionandtreatmentofchronicpain AT cohenstevenp antimicrobialtherapiesforchronicpainpart2thepreventionandtreatmentofchronicpain |